Mesalamine: molecular mechanisms & dependencies

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

Human evidence only

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

Where it participates (unsigned role)

Clinical remission occurred in 14/26 curcumin recipients versus 0/24 placebo recipients at week four.
Curcumin → Clinical remission of ulcerative colitis in the specified trial source_derived_draftungraded
Experimental context and source evidence
evidence_span
{"source_cache": "artifacts/curcumin-research/25724700.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "470d55e94365249fc0b737c0b177188f2d4a968cd148b71c3ee6c621189cd09e", "start_char": 0, "end_char": 1945, "text_sha256": "470d55e94365249fc0b737c0b177188f2d4a968cd148b71c3ee6c621189cd09e"}
experimental_model
Multicenter randomized trial in 50 mesalamine-treated adults
exposure
Curcumin 3 g/day or placebo for one month with continuing mesalamine
limitations
Adjunctive treatment, not curcumin monotherapy. Small study and wide confidence intervals; molecular mediation not demonstrated.
nutrient_topic
Curcumin research collection; topical membership is not evidence of a direct dietary effect. · Curcumin
organism
Homo sapiens
plain_language
Adding curcumin improved the trial's remission endpoint.
primary_references
[curcumin-p25724700] Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. (2015). https://pubmed.ncbi.nlm.nih.gov/25724700/ DOI: 10.1016/j.cgh.2015.02.019
tissue_or_cell_type
Mild-to-moderate active ulcerative colitis
Curcumin: metabolism, signaling and nutrient connections (2026-09-17) · lines 1035–1046
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Multicenter randomized trial in 50 mesalamine-treated adults · source_derived_draft · unverified_draft
### curcumin-uc-remission Clinical remission occurred in 14/26 curcumin recipients versus 0/24 placebo recipients at week four. Condition category: normal nutrient_topic: Curcumin research collection; topical membership is not evidence of a direct dietary effect. plain_language: Adding curcumin improved the trial's remission endpoint. organism: Homo sapiens tissue_or_cell_type: Mild-to-moderate active ulcerative colitis experimental_model: Multicenter randomized trial in 50 mesalamine-treated adults limitations: Adjunctive treatment, not curcumin monotherapy. Small study and wide confidence intervals; molecular mediation not demonstrated. exposure: Curcumin 3 g/day or placebo for one month with continuing mesalamine evidence_span: {"source_cache": "artifacts/curcumin-research/25724700.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "470d55e94365249fc0b737c0b177188f2d4a968cd148b71c3ee6c621189cd09e", "start_char": 0, "end_char": 1945, "text_sha256": "470d55e94365249fc0b737c0b177188f2d4a968cd148b71c3ee6c621189cd09e"} [curcumin-p25724700] Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. (2015). https://pubmed.ncbi.nlm.nih.gov/25724700/ DOI: 10.1016/j.cgh.2015.02.019
Complete structured claim and evidence
Clinical response occurred in 17/26 versus 3/24 participants.
Curcumin → Clinical response of ulcerative colitis in the specified trial source_derived_draftungraded
Experimental context and source evidence
evidence_span
{"source_cache": "artifacts/curcumin-research/25724700.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "470d55e94365249fc0b737c0b177188f2d4a968cd148b71c3ee6c621189cd09e", "start_char": 0, "end_char": 1945, "text_sha256": "470d55e94365249fc0b737c0b177188f2d4a968cd148b71c3ee6c621189cd09e"}
experimental_model
Multicenter randomized trial in 50 mesalamine-treated adults
exposure
Curcumin 3 g/day or placebo for one month with continuing mesalamine
limitations
Adjunctive treatment, not curcumin monotherapy. Small study and wide confidence intervals; molecular mediation not demonstrated.
nutrient_topic
Curcumin research collection; topical membership is not evidence of a direct dietary effect. · Curcumin
organism
Homo sapiens
plain_language
More participants also met the symptom-response criterion.
primary_references
[curcumin-p25724700] Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. (2015). https://pubmed.ncbi.nlm.nih.gov/25724700/ DOI: 10.1016/j.cgh.2015.02.019
tissue_or_cell_type
Mild-to-moderate active ulcerative colitis
Curcumin: metabolism, signaling and nutrient connections (2026-09-17) · lines 1048–1059
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Multicenter randomized trial in 50 mesalamine-treated adults · source_derived_draft · unverified_draft
### curcumin-uc-response Clinical response occurred in 17/26 versus 3/24 participants. Condition category: normal nutrient_topic: Curcumin research collection; topical membership is not evidence of a direct dietary effect. plain_language: More participants also met the symptom-response criterion. organism: Homo sapiens tissue_or_cell_type: Mild-to-moderate active ulcerative colitis experimental_model: Multicenter randomized trial in 50 mesalamine-treated adults limitations: Adjunctive treatment, not curcumin monotherapy. Small study and wide confidence intervals; molecular mediation not demonstrated. exposure: Curcumin 3 g/day or placebo for one month with continuing mesalamine evidence_span: {"source_cache": "artifacts/curcumin-research/25724700.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "470d55e94365249fc0b737c0b177188f2d4a968cd148b71c3ee6c621189cd09e", "start_char": 0, "end_char": 1945, "text_sha256": "470d55e94365249fc0b737c0b177188f2d4a968cd148b71c3ee6c621189cd09e"} [curcumin-p25724700] Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. (2015). https://pubmed.ncbi.nlm.nih.gov/25724700/ DOI: 10.1016/j.cgh.2015.02.019
Complete structured claim and evidence

The events it takes part in

A mechanism often involves more than two components. These are the full events, with every participant and its role.

Situations it appears in

Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

Open hypotheses

Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.

This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

Mesalamine